Product image of Jorveza (Budesonide) supplied by GNH India

Jorveza

Active Ingredient:
Budesonide
Origin:
EU

Jorveza (Budesonide)

Budesonide, the active ingredient in Jorveza, is a glucocorticoid presented as an oral suspension for oral use. It acts as an anti‑inflammatory and immunosuppressant, and is approved in the European Union for the management of Crohn’s disease in adult patients.

GNH India supplies Jorveza as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable access to this EU‑approved therapy. All batches are manufactured under GMP standards and undergo rigorous quality testing before distribution, ensuring consistency and safety for patients.

Manufacturer / TM Owner

Dr. Falk Pharma G.M.B.H.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Budesonide in Jorveza is used to treat inflammatory bowel disease, specifically Crohn’s disease, by reducing intestinal inflammation.

  • Crohn's disease: reduces intestinal inflammation and helps induce and maintain remission in adult patients.

How It Works

  • Budesonide binds to intracellular glucocorticoid receptors, forming a complex that translocates to the nucleus and modulates gene transcription. This action suppresses the production of pro‑inflammatory cytokines, inhibits immune cell activation, and stabilises lysosomal membranes, resulting in potent anti‑inflammatory and immunosuppressive effects within the gastrointestinal tract.

Side Effects

Budesonide may cause a range of adverse reactions, from mild to severe.

Common Side Effects

  • Oral candidiasis: fungal infection of the mouth.
  • Nausea: feeling of sickness or upset stomach.
  • Headache: mild to moderate head pain.
  • Abdominal pain: discomfort in the stomach area.
  • Dyspepsia: indigestion or heartburn.
  • Increased appetite: heightened desire for food.

Serious or Rare Side Effects

  • Adrenal suppression: reduced endogenous cortisol production.
  • Severe infection: increased susceptibility to bacterial, viral, or fungal infections.
  • Hypersensitivity reactions: rash, itching, or anaphylaxis.
  • Osteoporosis: loss of bone density with long‑term use.
  • Growth retardation: impaired growth in pediatric patients.
  • Thromboembolic events: rare blood clot formation.

Precautions & Warnings

Before initiating therapy, clinicians should evaluate patient history and monitor for potential complications.

  • Assess infection risk: screen for active infections before starting treatment.
  • Monitor adrenal function: watch for signs of adrenal insufficiency, especially with abrupt discontinuation.
  • Use lowest effective dose: aim to minimise systemic exposure.
  • Avoid abrupt withdrawal: taper the dose when discontinuing long‑term therapy.
  • Caution in hepatic impairment: adjust therapy as needed for liver dysfunction.
  • Store at ambient temperature: keep in the original container, protect from moisture and light.

Avoid Interactions

Budesonide may interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid)

  • Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase systemic exposure.
  • Concomitant systemic glucocorticoids: risk of additive corticosteroid effects.
  • Live vaccines: reduced vaccine efficacy and potential infection.

Moderate Interactions (Monitor Closely)

  • Moderate CYP3A4 inhibitors (e.g., erythromycin): may modestly raise levels.
  • Diuretics: may enhance hypokalaemia.
  • NSAIDs: increase risk of gastrointestinal ulceration.

Frequently Asked Questions

Jorveza contains budesonide, a glucocorticoid that is prescribed to treat Crohn’s disease in adults. It works by reducing inflammation in the gastrointestinal tract, helping to achieve and maintain remission of disease symptoms.

Budesonide binds to glucocorticoid receptors inside cells, altering gene expression to suppress the production of pro‑inflammatory cytokines and inhibit immune‑cell activation. This anti‑inflammatory action reduces gut inflammation characteristic of Crohn’s disease.

The dosage of Jorveza is determined individually by the prescribing clinician based on disease severity, patient weight, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for budesonide in pregnancy and lactation are limited. The decision to use Jorveza during pregnancy or while breastfeeding should be made by a healthcare professional after weighing potential benefits against possible risks.

To request Jorveza, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Jorveza delivers budesonide, a locally acting glucocorticoid with high first‑pass metabolism, offering potent anti‑inflammatory effects while limiting systemic exposure compared with systemic steroids. It is often preferred for mild‑to‑moderate disease when a targeted oral therapy is appropriate.

Store Jorveza at ambient temperature, preferably below 25 °C. Keep the suspension in its original container, protect it from moisture and direct light, and discard any product that appears discoloured or has an unusual odor.

Jorveza is taken orally as a suspension. The prescribed dose is measured with a calibrated spoon or oral syringe, and the medication should be shaken gently before each use to ensure uniform concentration.

Serious risks include adrenal suppression, severe infections, hypersensitivity reactions, osteoporosis with long‑term use, and, in rare cases, thromboembolic events. Patients should be monitored regularly for signs of these complications.

Jorveza is contraindicated in patients with known hypersensitivity to budesonide or any formulation components, in those with uncontrolled systemic infections, and in individuals receiving live vaccines without appropriate medical supervision.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Budesonide

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT